The current study demonstrated that PARK2 is a tumor suppressor gene in OS and exerts a profound anti-cancer activity in vitro and in vivo, including retarding growth, migration, invasion, metastasis, and angiogenesis by partly inhibiting the JAKT2/STAT3/VEGF pathway. This evidence concerns the gene VEGFA and neoplasm.